Arthritis and Cannabis: Why CBD Alone Falls Short and THC Makes the Difference

A rigorous Danish clinical trial published in the Journal of Cannabis Research reveals that CBD monotherapy at low doses is insufficient for managing chronic pain in rheumatological conditions like rheumatoid arthritis and ankylosing spondylitis. Even when serology tests show controlled joint inflammation, patients often experience persistent severe pain, morning stiffness, and fatigue—challenges that CBD alone cannot adequately address. The research demonstrates that THC-containing formulations provide additional therapeutic value beyond isolated CBD, challenging the widespread commercial narrative that cannabidiol is a universal solution. For Puerto Rico's arthritis patients seeking medical marijuana options, this finding underscores the importance of comprehensive cannabinoid profiles rather than single-compound approaches.